ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Japanese drug companies Astellas Pharma and Daiichi Sankyo have agreed to exchange libraries of pharmaceutically active compounds for use in high-throughput screening. Starting next month, the partners will provide each other with roughly 400,000 compounds, including a “significant number” of proprietary ones, for a period of three years. Each firm will be able to screen the other’s compounds without restriction to develop new drugs for any human disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter